CDChen Dong

Chen Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chen Dong has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Yuemin Nan

    Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, China

    3 shared publications
  • Lu Li

    Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital & Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base, Shijiazhuang, Hebei Province, 050051, People’s Republic of China

    2 shared publications
  • Mengmeng Hou

    Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China

    2 shared publications
  • Xiaoxiao Zhang

    Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University & Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang, Hebei, China

    2 shared publications
  • Xiwei Yuan

    Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China

    2 shared publications
  • Yao Dou

    Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei Province, China

    2 shared publications

Latest Publications

  • Open Access

    The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study

    by Yao Dou, Jiawei Cui, Qi Gu, Xiwei Yuan, Mengmeng Hou, Wenjing Ni, Chen Dong, Chudi Chang, Jinhua Shao, Qiuling Wang, et al.

    Background: Cardiovascular disease (CVD) has emerged as the most significant complication and leading cause of death among metabolic-associated fatty liver disease (MAFLD). Objectives: This study aims to investigate the CVD risk among MAFLD subgroups. Design: Data of participants from June 2017 to January 2023 in the Physical Examination Center of the Third Hospital of Hebei Medical University were collected. MAFLD were divided into four subgroups: metabolic healthy lean/normal weight MAFLD (MHL), metabolic healthy overweight/obese MAFLD (MHO), metabolic dysfunctional lean/normal weight MAFLD (MDL), and metabolic dysfunctional overweight/obese MAFLD (MDO). Methods: The risk assessment for atherosclerotic CVD was performed based on the flowchart for primary prevention risk assessment in Chinese adults. Results: The proportions of MHL, MHO, MDL, and MDO were 0.77% ( n = 185), 10.05% ( n = 2406), 1.29% ( n = 310), and 16.86% ( n = 4038), respectively. After adjustment for gender, age, smoking history, drinking history, and significant liver fibrosis, the subgroup of MAFLD was still an independent risk factor for high adverse cardiovascular events (HACE). Compared with the MHL, the MDL had the highest risk, followed by MDO (all p < 0.05), and there was no significant difference between MHO and MHL. We performed regression analysis according to age (65 years) and gender (male or female), respectively, and the results were similar to those of the total population. Conclusion: MAFLD is associated with a higher risk of CVD, especially in MDO. Classification of MAFLD based on body mass index and metabolic status helps in risk stratification, which will mitigate or prevent the development of CVD.


  • Open Access

    Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B

    by Siyu Zhang, Xiaoxiao Zhang, Huiming Jin, Yao Dou, Lu Li, Xiwei Yuan, Chen Dong, Mengmeng Hou, Yue-Min Nan, Jia Shang

    The impact of nonalcoholic fatty liver disease (NAFLD) on the treatment outcome of chronic hepatitis B (CHB) is undefined and deserves an in-depth investigation.


  • Identification of potential plasma markers for hepatitis B virus‐related chronic hepatitis and liver fibrosis/cirrhosis

    by Dandan Zhao, Songhao Yu, Peilin Guo, Xiaoxiao Zhang, Yuhui Tang, Chen Dong, Suxian Zhao, Lu Li, Zaid Al‐Dhamin, Rong Ai, et al.

    The aim of this study was to identify potential plasma biomarkers for hepatitis B virus (HBV)‐related liver diseases. High‐throughput transcriptome sequencing analysis was performed on five patients with chronic hepatitis B (CHB), five patients with HBV‐associated liver fibrosis/liver cirrhosis (LF/LC), and four healthy participants. By short time‐series expression miner and functional analysis, aquaporin 1 (AQP1), dystroglycan 1 (DAG1), and hemoglobin subunit beta (HBB) were identified as potential biomarkers. Immunohistochemical analysis revealed that the expression levels of AQP1, DAG1, and HBB were upregulated in the three groups. Subsequent enzyme‐linked immunosorbent assay tests on the training cohort ( n = 150) indicated that the plasma levels of AQP1 and DAG1 were highest in LF/LC patients, followed by those in CHB patients, and the lowest in healthy controls. APAD model, a diagnostic panel incorporating age, platelet, AQP1, and DAG1 levels, exhibited the strongest stratification ability to distinguish LF/LC patients from CHB patients, and to differentiate CHB patients from healthy controls. Furthermore, the diagnostic accuracies of the biomarkers and APAD model were verified in an independent cohort consisting of 230 participants. In conclusion, both AQP1 and DAG1 have good diagnostic values and APAD model greatly enhances the diagnostic accuracy for HBV‐related hepatic diseases.